Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma.

@article{Yao2013GemcitabineOA,
  title={Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma.},
  author={Yi-yun Yao and Yong Tang and Qi Zhu and Yan Zhuang and Yi-min Cheng and Lei Wang and Li-fang Zou},
  journal={Leukemia & lymphoma},
  year={2013},
  volume={54 6},
  pages={
          1194-200
        }
}
The development of a more effective and less toxic salvage regimen remains a major challenge in elderly patients with relapsed and/or refractory peripheral T-cell lymphoma (PTCL). From April 2004 to May 2010, we used a new salvage regimen combining gemcitabine, oxaliplatin and dexamethasone (GemOD) in 24 elderly patients with relapsed (n = 11) or refractory (n = 13) PTCL unsuitable for high dose therapy. GemOD consisted of gemcitabine (1000 mg/m(2) on day 1), oxaliplatin (100 mg/m(2) on day 1… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-5 of 5 extracted citations

T-cell lymphomas, a challenging disease: types, treatments, and future

International Journal of Clinical Oncology • 2016
View 1 Excerpt